The ligand binding approach to receptor characterization is a convenient way of monitoring receptor numbers and distribution, assessing pharmacological specificity and following the receptor during purification procedures. Ligand binding assays using the high-affinity, pseudo-irreversible antagonist a-bungarotoxin have made an enormous contribution to the understanding of the muscle nicotinic acetylcholine receptor (nAChR) and its counterpart in Torpedo electroplax [l] . The success of a-bungarotoxin in this respect prompted its use to seek out and characterize nAChR in the nervous system. Despite the clearcut identification of specific binding sites for a-bungarotoxin in brain and in autonomic ganglia, this toxin fails to act as a nicotinic antagonist in the majority of instances in which it has been examined [2] . This was surprising since a-bungarotoxin binding sites in nervous tissue are clearly nicotinic in character, binding being displaced by nicotine, acetylcholine and other competitive nicotinic drugs.
In 1980, the first substantial characterization of ligand binding sites for ["] [ 'HINicotine binding sites and "'1-a-bungarotoxin binding sites do not co-purify [ 51, they have quite different anatomical distributions in the brain [6] and give distinctive subunit patterns on SDS/ PAGE [7] . But given the uncertainty about the receptor status of neuronal a-bungarotoxin sites, it would be imprudent to elevate the tritiated agonist binding sites to nAChR status in the absence of corroborative evidence. (a-Bungarotoxin-N a + insensitive) This dilemma reflects the lack of pharmacological tools for probing nAChR, although this is offset by the fortuitous occurrence of potent and selective natural products [22] . In the absence of subtype-specific ligands necessary for clarification of the relationship between binding sites and functional nAChR, other strategies must be sought. [27] . The specificity of this response was evident from the lack of effect on K + -evoked release. This result is therefore consistent with the identity of presynaptic nAChR with ['Hlnicotine binding sites. The occurrence of presynaptic nAChR is also supported by immunohistochemical experiments that reveal nAChR labelling in axons [28] . However, the antibody used (mAb 270) recognizes the structural subunit BZ, and therefore this study does not distinguish between a3B2 and a4B2 subtypes of nAChR Similarly, in situ hybridizations recognize the expression of both a 3 and 84 transcripts in substantia nigra, for example, and it has been proposed that one subtype may be transported to presynaptic locations [29] . Because mRNA is only present in the cell bodies, this approach does not clarify which subtype might be presynaptic (although the authors propose that it is a 3 [26] ). Of course, it is also possible that both subtypes have both pre-and post-synaptic localizations in brain neurons, as is the case for D2 and D3 receptors for example [ 301.
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T o pursue the question of nAChR subtype localization and function in the central nervous system, more specific pharmacological tools are urgently required; the consensus from available data favours the ['Hlnicotine binding site (a4B2) as the correlate of presynaptic nAChR on striatal dopaminergic neurons, although the possibility that a3B2 receptors also have a presynaptic role cannot at present be excluded.
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Introduction
The inhibitory neurotransmitter y-aminobutyrate (GABA) elicits its physiological effects through interactions with two distinct classes of cell-surface receptor in the central nervous system. The GABA, receptor is a member of the superfamily of ligandgated ion channels of which the nicotinic acetylcholine and glycine receptors are also members (see [ 1, 21 for reviews). The GABA, receptor, which displays a neuronal distribution and pharmacology distinct from that of the GABAA receptor, is G-protein linked [ 31.
The GABA, receptor possesses a complex pharmacology and is regulated allosterically at a number of distinct sites. Thus, GABA or GABA analogues, such as muscimol, regulate the opening and closing of the ion channel on a time scale of milliseconds. Radioligand binding studies have defined at least three other high-affinity binding sites on the receptor complex, namely those for the anxiolytic benzodiazepines, cage-convulsants (e.g. t-butyl bicyclophosphorothioate) and avermectin B,, [4] . In addition, the activity of the GABAA receptor is also subject to modulation by a variety of hypnotic agents, including depressant barbiturates and anaesthetics [5, 61 and by some endogenous steroids [7-91. However, in the absence of suitable high-affinity ligands which can be displaced competitively by barbiturates or steroids, the pre-~~ Abbreviation used: GABA, y-aminobutyrate.
*To whom correspondence should be addressed. cise nature of the interaction between these drugs and the GABA, receptor has remained unclear.
Molecular structure of the GABAA receptor
The affinity-purified GABA, receptor is a heterooligomeric glycoprotein. Two polypeptides of molecular mass 53000 and 57000 Da (a and j3 subunits, respectively) were obtained after purifica- The complete primary sequences of the a and j3 subunits of the bovine GABA, receptor were deduced from the corresponding cDNA sequences
[ 191. As a result of these studies, several common features of the a and j3 polypeptides were revealed.
The hydropathy profiles predicted both subunits contained four hydrophobic transmembrane
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